If you look at what is going on in the Background at AFFy is very interesting.
Though both Arlene/Ann Marie gave the presentation they did not spell out when they intend to meet with FDA!! Seems to be a very confidential information.
They are ramping the Sales team for commmercializing the product. On top of it Takeda is pretty confident with the available data for Dialysis patients. They are going ahead with the mfg process too using contract manufacturers.
These Jap's especially from a company like Takeda has enormous talent pool to draw and analyze the AFFY data for filing for NDA and commercialization possibilities.
The Option allocation is over and there is NO incentive for Arlene to wait any longer here. A buyout will add few more millions to their kitties and it is done.
For me, Takeda will move very soon before any massive news leakage to buy AFFY out!
IMO the parties directly involved with FDA were not allowed to broadcast the news, but other people could talk about the date of the meeting:
FDA advisory panel to discuss the use of erythropoeisis-stimulating agents in the treatment of patients with chronic kidney failure. Amgen(AMGN_) (Aranesp, Epogen), Johnson & Johnson (Procrit) and Affymax(AFFY_) (Hematide)."
vinh: I agree with you! The guy jstock was right, when he said "Wait till they allot the options".
I should have waited instead of blocking the funds. Now it is over, there is NO incentive for Arlene to wait any longer.
You need to have the shares when the News hit the wires. Takeda's conclusion that they will be filing NDA for Dialysis indication, is a clear information, which the shorts don't get. All the material information is disclosed to the public, including their proposed prelim meeting with FDA and their intention to file NDA for sub-sect!
I believe someone is going to get squeezed bigtime very soon!
Jag, it is possible that a Takeda NDA (Hematide) would be better received by the FDA, given their size, production capabilities, distribution channel, and experience than the same filing submitted by AFFY.
Right now despite paying so much money, Takeda is doing the heavy lifting in terms of filing for NDA, work related to assessing the clinical data and even for the preliminary work to meet with FDA!
Arlene is not qualified enough to conduct these type of scientific data, she is a business woman who could conclude a deal.
That is why I said, after this options allotment, there is NO necessity for Arlene to move forward and that too when there may be risks!
If Takeda sees a golden goose here, which JMHO they do, Arlene will give and walk away. Majority of the BOD hold substantial shares here, and they did not sell out.
They are waiting for this buyout to happen, JMHO!
THere is NO RISK here. $7 Cash, very minimal Cash burn, 400 MLN NOL and assets like Peptide platform and patents. Intrinsic value is close to $15, with Zero value to Hematide.